DNA Link Inc (127120) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DNA Link Inc (127120) has a cash flow conversion efficiency ratio of -0.044x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.05 Billion ≈ $-1.39 Million USD) by net assets (₩46.15 Billion ≈ $31.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DNA Link Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how DNA Link Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does DNA Link Inc carry for a breakdown of total debt and financial obligations.
DNA Link Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DNA Link Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
-0.055x |
|
Zhejiang Shengyang Science
SHG:603703
|
0.010x |
|
STEVANATO GROUP SPA O.N.
F:87N
|
0.063x |
|
Prima Andalan Mandiri Tbk PT
JK:MCOL
|
0.113x |
|
Shinry Technologies Co Ltd Class A
SHE:300745
|
0.147x |
|
Total Gabon
F:RZW
|
0.043x |
|
Jiangsu Yawei Machine Tool Co Ltd
SHE:002559
|
0.058x |
|
Jiayuan Science and Technology Co.Ltd.
SHE:301117
|
N/A |
Annual Cash Flow Conversion Efficiency for DNA Link Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of DNA Link Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see how much is DNA Link Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩68.59 Billion ≈ $46.48 Million |
₩-9.39 Billion ≈ $-6.36 Million |
-0.137x | +49.49% |
| 2024-12-31 | ₩25.03 Billion ≈ $16.96 Million |
₩-6.78 Billion ≈ $-4.60 Million |
-0.271x | -41.54% |
| 2023-12-31 | ₩26.28 Billion ≈ $17.81 Million |
₩-5.03 Billion ≈ $-3.41 Million |
-0.191x | -686.44% |
| 2022-12-31 | ₩27.89 Billion ≈ $18.90 Million |
₩910.27 Million ≈ $616.88K |
0.033x | +116.64% |
| 2021-12-31 | ₩32.77 Billion ≈ $22.21 Million |
₩-6.43 Billion ≈ $-4.36 Million |
-0.196x | -993.88% |
| 2020-12-31 | ₩38.70 Billion ≈ $26.23 Million |
₩849.38 Million ≈ $575.62K |
0.022x | +116.32% |
| 2019-12-31 | ₩9.66 Billion ≈ $6.55 Million |
₩-1.30 Billion ≈ $-880.41K |
-0.134x | -64.54% |
| 2018-12-31 | ₩19.60 Billion ≈ $13.29 Million |
₩-1.60 Billion ≈ $-1.09 Million |
-0.082x | +22.37% |
| 2017-12-31 | ₩23.66 Billion ≈ $16.03 Million |
₩-2.49 Billion ≈ $-1.69 Million |
-0.105x | +94.93% |
| 2016-12-31 | ₩1.82 Billion ≈ $1.23 Million |
₩-3.77 Billion ≈ $-2.55 Million |
-2.076x | -523.69% |
| 2015-12-31 | ₩11.20 Billion ≈ $7.59 Million |
₩-3.73 Billion ≈ $-2.53 Million |
-0.333x | -1698.26% |
| 2014-12-31 | ₩7.73 Billion ≈ $5.24 Million |
₩-143.14 Million ≈ $-97.00K |
-0.019x | +58.15% |
| 2012-12-31 | ₩17.70 Billion ≈ $12.00 Million |
₩-783.00 Million ≈ $-530.63K |
-0.044x | +79.15% |
| 2011-12-31 | ₩11.52 Billion ≈ $7.81 Million |
₩-2.44 Billion ≈ $-1.66 Million |
-0.212x | -- |
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more